BA CGA - XBiotech VP Sec

XBIT Stock

USD 7.35 0.54 7.93%

Insider

BA CGA is VP Sec of XBiotech

Age	55
Address	5217 Winnebago Lane, Austin, TX, United States, 78744
Phone	512 386 2900
Web	https://www.xbiotech.com

XBiotech Management Efficiency

The company has return on total asset (ROA) of (0.1203) % which means that it has lost $0.1203 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1575) %, meaning that it created substantial loss on money invested by shareholders. XBiotech's management efficiency ratios could be used to measure how well XBiotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.11 in 2024. Return On Capital Employed is likely to drop to -0.18 in 2024. Total Current Liabilities is likely to gain to about 9.4 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 209.4 M in 2024.

Compare XBiotech to Peers

Predict price of XBiotech

XBiotech currently holds 7.77 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. XBiotech has a current ratio of 28.41, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about XBiotech's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Mark Lappe	Inhibrx	57
	Steven Almo	Cue Biopharma	63
	Quinn Deveraux	Inhibrx	N/A
	Kenneth MD	Cue Biopharma	64
	JD MSc	Cue Biopharma	61
	Jo PalmerPhillips	Eliem Therapeutics	N/A
	Patrick Amstutz	Molecular Partners AG	49
	Seth Lewis	Molecular Partners AG	N/A
	James JD	Eliem Therapeutics	58
	MBA MD	Eliem Therapeutics	63
	Andreas EMBA	Molecular Partners AG	58
	BS CPA	Inhibrx	42
	Erin Lavelle	Eliem Therapeutics	47
	Alexander Zurcher	Molecular Partners AG	49
	Michael Pitzner	Molecular Partners AG	N/A
	, MBA	Molecular Partners AG	51
	Susan MS	Eliem Therapeutics	N/A
	Robert MBA	Eliem Therapeutics	56
	Thomas Schwerzmann	Molecular Partners AG	N/A
	Dr III	Cue Biopharma	48

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company was incorporated in 2005 and is headquartered in Austin, Texas. Xbiotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 96 people. XBiotech (XBIT) is traded on NASDAQ Exchange in USA. It is located in 5217 Winnebago Lane, Austin, TX, United States, 78744 and employs 82 people. XBiotech is listed under Biotechnology category by Fama And French industry classification.

Management Performance

	Return On Equity	-0.16
	Return On Asset	-0.12

XBiotech Leadership Team

Elected by the shareholders, the XBiotech's board of directors comprises two types of representatives: XBiotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of XBiotech. The board's role is to monitor XBiotech's management team and ensure that shareholders' interests are well served. XBiotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, XBiotech's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Benjamn Guzmn, Sr Fin
	Angela Hu, Principal Finance
	John Simard, Founder, Chairman, CEO and Pres
	Lisa Simard, Inc USA
	Sushma Shivaswamy, Chief Officer
	BA CGA, VP Sec

XBiotech Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is XBiotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.16
	Return On Asset	-0.12
	Current Valuation	50.94 M
	Shares Outstanding	30.48 M
	Shares Owned By Insiders	35.10 %
	Shares Owned By Institutions	16.18 %
	Number Of Shares Shorted	848.26 K
	Price To Earning	1.21 X
	Price To Book	1.17 X
	Price To Sales	12.23 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for XBiotech Stock Analysis

When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC